IMMUNEXT, INC.

Address

1 MEDICAL CENTER DRIVE
LEBANON, NH, 03756-1000

http://www.immunext.com

Information

DUNS: 967719241
# of Employees: 12

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Targeting the checkpoint regulator VISTA for treatment of inflammatory disease

    Amount: $299,938.00

    ImmuNext has identified and developed a putative lead anti VISTA monoclonal antibody mAb that we aim to bring to the clinic for the treatment of human autoimmune disease VISTA is a member of the hi ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  2. Safe and effective anti CD154 antibodies for therapeutic intervention

    Amount: $912,191.00

    Abstract CD CD L is a key target for immunomodulation due to its central role in controlling the activation of the immune system This well studied immune switch has been the focus of extensi ...

    SBIRPhase II2016Department of Health and Human Services
  3. Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease

    Amount: $1,949,257.00

    DESCRIPTION provided by applicant Systemic lupus erythematosus SLE is a devastating autoimmune disease that most commonly affects women in their child bearing years SLE attacks multiple organ sy ...

    STTRPhase II2014Department of Health and Human Services
  4. Safe And Effective Anti-CD154 Antibodies For Therapeutic Intervention

    Amount: $290,914.00

    DESCRIPTION (provided by applicant): There is compelling evidence that ?CD154 treatment has great potential in autoimmunity and graft rejection. Autoimmunity. Clinical efficacy of ?CD154 t ...

    STTRPhase I2013Department of Health and Human Services
  5. Safe and effective anti CD154 antibodies for therapeutic intervention

    Amount: $2,960,698.00

    DESCRIPTION provided by applicant In both animal proof of concept studies and preliminary clinical trials there is ample data demonstrating the potential therapeutic benefits o CD blockade for ...

    SBIRPhase II2013Department of Health and Human Services
  6. Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): The immune system depends upon an exquisite balance between positive and negative signals to maintain proper function. However, disruptions of this balance can lea ...

    STTRPhase I2012Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government